|18.75|| -1.00 / -5.06%|
Epizyme, Inc. operates as a clinical stage biopharmaceutical company. It discovers, develops and plans to commercialize novel epigenetic therapies for patients with cancer and other diseases. The company engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases. Its products include Tazemetostat, which is used for the treatment of multiple types of hematological malignancies and genetically defined solid tumors; and Pinometostat, which is used for treatment of patients with MLL-r, a genetically defined acute leukemia. Epizyme was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA.
|Robert B. Bazemore||President, CEO, Secretary & Director|
|Matthew E. Ros||Chief Operating Officer|
|Suzanne Fleming||Treasurer, Chief Accounting Officer & SVP-Finance|
|Michael Boretti||Vice President-Business Development|
|Susan E. Graf||Chief Business Officer|